Protara Therapeutics (TARA) Cash from Operations (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Cash from Operations data on file, last reported at 21343000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 45.06% year-over-year to 21343000.0 in Q1 2026; TTM through Mar 2026 was 62995000.0, a 56.93% decrease from a year earlier, with the FY2025 full-year figure at 56365000.0, down 57.41% from the prior year.
• Cash from Operations for Q1 2026 stood at 21343000.0, down from 16950000.0 in the prior quarter.
• Over the last five years, Cash from Operations for TARA reached as high as 5026000.0 in Q4 2022 and fell as low as 21343000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 10442941.18 across 5 years, with a median of 9408000.0 in 2023.
• Across the five-year window, Cash from Operations surged 45.93% in 2022 and plunged 83.64% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 5026000.0 in 2022, then slumped by 73.1% to 8700000.0 in 2023, then declined by 6.99% to 9308000.0 in 2024, then slumped by 82.1% to 16950000.0 in 2025, then fell by 25.92% to 21343000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 21343000.0 in Q1 2026, 16950000.0 in Q4 2025, and 12452000.0 in Q3 2025.